Disease · MONDO_0005062

lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. lymphoma. Diseases, record MONDO_0005062. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005062

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: lymphoma; Open Targets
Open Targets ID: MONDO_0005062; Open Targets
Other names: lymphoid cancer, lymphoma (Hodgkin and non-Hodgkin), lymphoma (Hodgkin's and non-Hodgkin's), lymphoma, malignant, lymphomatous, malignant lymphoma; Open Targets
Disease Ontology: DOID:0060058; Disease Ontology
MeSH: D008223; MeSH
NCI Thesaurus: C3208; NCI Thesaurus
Orphanet: ORPHA:223735; Orphanet
Highest stage of its drugs: Approval, for 21 of its 462 drugs, from DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs462

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Approval	DailyMed	74	70	70	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	16	15	15	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	21	14	14	Drugs and targets
PLERIXAFOR	CHEMBL18442	Small molecule	Approval	EMA Human Drugs	11	10	10	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Approval	DailyMed	21	4	4	Drugs and targets
RASBURICASE	CHEMBL1201594	Enzyme	Approval	DailyMed	5	4	4	Drugs and targets
PEGASPARGASE	CHEMBL2108546	Enzyme	Approval	PMDA	4	3	3	Drugs and targets
ALLOPURINOL	CHEMBL1467	Small molecule	Approval	DailyMed	53	2	2	Drugs and targets
TAFASITAMAB	CHEMBL4298047	Antibody	Approval	DailyMed	3	1	1	Drugs and targets
CORTISONE ACETATE	CHEMBL1650	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets

1 to 10 of 462

See all 462 drugs

Targets383

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	16	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	16	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	16	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	16	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	16	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	16	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	16	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	16	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	16	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	16	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 383

See all 383 targets

Trials569

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 19 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00230178	Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome	Phase 3	280	2009-12-31	Tumor Lysis Syndrome, Cancer, Hyperuricemia	ALLOPURINOL, RASBURICASE	Its record names the disease	ClinicalTrials.gov
NCT00436618	Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment	Phase 2	277	2013-07-30	Leukemia, Lymphoma, Lymphoproliferative Disorder	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01810588	Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation	Phase 2	270	2024-10-09	Hematologic Malignancies	FLUDARABINE, MELPHALAN, MYCOPHENOLATE MOFETIL, RITUXIMAB, TACROLIMUS ANHYDROUS	Its record names the disease	ClinicalTrials.gov
NCT02663518	A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors	Phase 1	249	2024-05-10	Hematologic Malignancies, Solid Tumor	NIVOLUMAB, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01695005	A Study of LY3039478 in Participants With Advanced Cancer	Phase 1	247	2025-12-26	Neoplasms, Neoplasm Metastasis, Lymphoma	CRENIGACESTAT, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT01572662	Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning	Phase 2	201	2023-06-29	Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Diseases, Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome	BUSULFAN, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT01109069	Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia	Phase 2	199	2020-05-07	B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Well-differentiated Lymphocytic Lymphoma, B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Waldenstrom Macroglobulinemia, Burkitt Lymphoma, B-Cell Diffuse Lymphoma	IBRUTINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01092182	Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma	Phase 2	194	2021-10-19	Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma	CYCLOPHOSPHAMIDE, DOXORUBICIN, ETOPOSIDE, PREDNISONE, RITUXIMAB, VINCRISTINE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00531284	Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma	Phase 1/2	184	2015-12-09	Ovarian Cancer, Renal Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Solid Tumors, Multiple Myeloma, Lymphoma	CARFILZOMIB	Its record names the disease	ClinicalTrials.gov
NCT01010217	Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide	Phase 2	176	2020-01-07	Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies	CYCLOPHOSPHAMIDE, FILGRASTIM, FLUDARABINE, MELPHALAN, MESNA, MYCOPHENOLATE MOFETIL, RITUXIMAB, TACROLIMUS ANHYDROUS, THIOTEPA	Its record names the disease	ClinicalTrials.gov

1 to 10 of 569

See all 569 trials

Comparisons in its trials63

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: Overall Survival	16 of 49	47 of 150	199	NCT01572662	Trial comparisons
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: Non-Relapse Mortality Rate (NRM)	2 of 49	8 of 150	199	NCT01572662	Trial comparisons
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: Overall Survival	29 of 49	93 of 150	199	NCT01572662	Trial comparisons
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: deaths from any cause	31 of 49	93 of 150	199	NCT01572662	Trial comparisons
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: serious adverse events	6 of 49	8 of 150	199	NCT01572662	Trial comparisons
NiCord® (Omidubicel) vs Unmanipulated CBU(s): First Grade 2/3 Bacterial or Invasive Fungal Infections by 100 Days Following Transplantation	24 of 62	38 of 63	125	NCT02730299	Trial comparisons
NiCord® (Omidubicel) vs Unmanipulated CBU(s): Number of Participants With Platelet Engraftment by 42 Days Post-transplantation	34 of 62	22 of 63	125	NCT02730299	Trial comparisons
T Cell Depletion Transplant Participants vs Stem Cell Donors: deaths from any cause	14 of 58	0 of 58	116	NCT00378534	Trial comparisons
T Cell Depletion Transplant Participants vs Stem Cell Donors: serious adverse events	14 of 58	0 of 58	116	NCT00378534	Trial comparisons
BeEAM vs BEAM: deaths from any cause	4 of 53	6 of 55	108	NCT02278796	Trial comparisons

1 to 10 of 63

See all 63 comparisons in its trials

Papers from its trials267

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41556942	RESULT	1	PubMed
40499147	RESULT	1	PubMed
39846804	RESULT	1	PubMed
36669146	RESULT	1	PubMed
35914224	RESULT	1	PubMed
35484319	RESULT	1	PubMed
35262780	RESULT	1	PubMed
31894292	RESULT	1	PubMed
31882719	RESULT	1	PubMed
31831767	RESULT	1	PubMed

1 to 10 of 267

See all 267 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005062

GET https://conductscience.org/api/diseases/v1/MONDO_0005062/drugs?page=2

API reference For AI assistants